Lacrat (Ticagrelor)

Ticagrelor is a reversible antagonist of the platelet P2Y12 ADP receptor. By binding to this receptor, it blocks ADP‑mediated activation of the glycoprotein IIb/IIIa complex, which is essential for platelet aggregation. This inhibition prevents thrombus formation while allowing normal platelet function to return quickly after the drug is stopped.

The dosing regimen for Lacrat is determined by the prescribing clinician based on the patient’s clinical condition, renal function and concomitant therapies. Ticagrelor is typically initiated with a loading dose followed by a maintenance dose, but the exact amount and schedule must be individualized by a qualified healthcare professional.

Safety of ticagrelor in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To request Lacrat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lacrat (ticagrelor) differs from clopidogrel and prasugrel in that it binds reversibly to the P2Y12 receptor and does not require metabolic activation, leading to a faster onset and offset of action. Clinical trials have shown ticagrelor to provide greater reduction in cardiovascular events, though it may be associated with a higher incidence of dyspnea.

Lacrat tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, direct sunlight and excessive heat to maintain stability and potency throughout its shelf life.

Lacrat is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Administration can be with or without food, but patients should follow the prescriber’s instructions regarding timing relative to meals.

The most serious risks include severe or life‑threatening bleeding, such as intracranial hemorrhage or gastrointestinal bleeding, and rare cases of thrombocytopenia or severe allergic reactions. Patients should be monitored for signs of excessive bleeding and advised to seek immediate medical attention if they experience symptoms like sudden weakness, severe headache or unexplained bruising.

Lacrat is contraindicated in patients with active pathological bleeding, a history of intracranial hemorrhage, severe hepatic impairment, or known hypersensitivity to ticagrelor or any of its excipients. It should also be avoided in patients taking strong CYP3A4 inhibitors unless the prescriber determines the benefits outweigh the risks.